Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mBio
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Guest Editorial

RTS,S Malaria Vaccine and Increased Mortality in Girls

Sabra L. Klein, Frank Shann, William J. Moss, Christine S. Benn, Peter Aaby
Sabra L. Klein
aW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Shann
bDepartment of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Moss
cDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine S. Benn
dResearch Centre for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institute, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Aaby
eBandim Health Project, Indepth Network, Bissau, Guinea-Bissau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/mBio.00514-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

The views expressed in this Guest Editorial do not necessarily reflect the views of this journal or of ASM.

GUEST EDITORIAL

Malaria was estimated to result in 214 million clinical cases and 438,000 deaths in 2015, primarily in children under 5 years of age. In Africa, malaria causes approximately 10% of all deaths in children under 5 years of age. The RTS,S/AS01 malaria vaccine has been tested in young children in phase III clinical trials and shown to be 18 to 36% efficacious against clinical malaria (1). Although the vaccine may be efficacious against clinical malaria, it does not however reduce overall mortality.

The World Health Organization (WHO) recently published a position paper on malaria vaccines (2), with emphasis on the RTS,S/AS01 vaccine. Although the vaccine has had modest efficacy, the data in Table 1 show that RTS,S was associated with higher all-cause mortality in girls (mortality ratio, 1.91; 95% confidence interval [CI], 1.30 to 2.79; P = 0.0006) but not in boys (mortality ratio, 0.84; 95% CI, 0.61 to 1.17; P = 0.3343) in both age groups in which the vaccine was tested (i.e., 6 to 12 weeks and 5 to 17 months) (http://www.gsk-clinicalstudyregister.com/files2/9a7b7726-34e2-418d-bea6-c3fb071fd51c). The sex-differential effect is highly significant (P = 0.001). There also was a tendency for RTS,S to be associated with a higher risk of fatal malaria in girls (malaria mortality ratio, 1.90 [0.82 to 4.37]) but not in boys (malaria mortality ratio, 1.07 [0.52 to 2.18]). It is counterintuitive that there was no reduction in fatal malaria associated with RTS,S; however, RTS,S was associated with a twofold-higher case fatality ratio in children who got severe malaria (3).

View this table:
  • View inline
  • View popup
TABLE 1 

RTS,S malaria vaccine and mortality by sex

View this table:
  • View inline
  • View popup
TABLE 2 

Female-male mortality risk ratio in RTS,S malaria vaccine recipients

The WHO has speculated that the increased mortality in girls was “largely due to the low female mortality in the control arm” and “could be due to chance” (2), despite the P value of 0.0006 for girls and a mortality rate after RTS,S of 2.4% in girls compared to 1.8% in boys (risk ratio, 1.33 [1.02 to 1.74]) (Table 2). Although the WHO could be correct in speculating that this finding was due to chance, these numbers suggest a need for caution and additional research. Before RTS,S is introduced into routine vaccination schedules, we should determine whether RTS,S/AS01 increases mortality in girls and investigate possible mechanisms.

There is precedent for the observation that infant girls experience increased mortality following receipt of vaccines. For example, in the 1980s, when the high-titer measles vaccine (HTMV) was introduced to prevent measles in children under 9 months of age, there was a twofold increase in all-cause mortality in girls, but no increase in boys, which led to withdrawal of the vaccine (4). It was subsequently determined that the increased mortality occurred only among girls who received diphtheria-tetanus-pertussis (DTP) vaccine after HTMV and not among girls who received HTMV after their last dose of DTP (5). The interaction between HTMV and DTP may have caused nonspecific negative effects on all-cause mortality in girls but not boys. Evidence from multiple studies of nonlive vaccines, including DTP and the inactivated polio vaccine (IPV), show that these nonlive vaccines have greater detrimental effects for girls than boys (5, 6). Therefore, the increased female mortality after RTS,S/AS01 should not be dismissed as an unexpected finding that occurred by chance. Further clinical studies should explore whether girls need lower doses of the RTS,S/AS01 vaccine or should receive the vaccine with or separately from other vaccines or at different ages than boys.

Preclinical studies in animal models can help provide insights into the biological basis of these observations, but here too, analysis of potential sex effects has been lacking. Published studies of RTS,S or recombinant circumsporizoite protein in mice and nonhuman primates have only reported using adult females or have not reported the sex of the animals (7–9). Generally, in the fields of immunology, vaccinology, and infectious diseases, investigators either do not report the sex of their animals or predominately use female animals (10). This “one size fits all” approach to vaccine research is not working. Preclinical studies should consider how both age and sex affect vaccine responses and outcomes. RTS,S vaccine could also be used to uncover immunological mechanisms for a possible increase in mortality after RTS,S vaccination among girls but not boys.

The RTS,S vaccine is modestly effective at reducing clinical malaria in children, but the sex differences in all-cause mortality should be rigorously studied in both clinical trials and experimental animal models, particularly in light of prior experience with the HTMV. We seek to raise awareness about the need for additional research into how the RTS,S vaccine and, possibly, other vaccines are associated with greater mortality in girls but not boys. This will only be achieved if age and sex are considered in a priori hypotheses in vaccine trials to identify and address potential risks early in the vaccine development process.

ACKNOWLEDGMENTS

The work on the nonspecific effects of vaccines was supported by European Union FP7 support for OPTIMUNISE (grant number Health F3-2011-261375) and the Danish National Research Foundation (grant number DNRF108).

  • Copyright © 2016 Klein et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. RTS/S Clinical Trials Partnership
    . 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386:31–45. doi:10.1016/S0140-6736(15)60721-8.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. WHO
    . 2016. Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec 91:33–52.
    OpenUrl
  3. 3.↵
    1. Aaby P,
    2. Rodrigues A,
    3. Kofoed P-E,
    4. Benn CS
    . 2015. RTS,S/AS01 malaria vaccine and child mortality. Lancet 366:1735–1736.
    OpenUrl
  4. 4.↵
    1. Aaby P,
    2. Knudsen K,
    3. Whittle H,
    4. Lisse IM,
    5. Thaarup J,
    6. Poulsen A,
    7. Sodemann M,
    8. Jakobsen M,
    9. Brink L,
    10. Gansted U
    . 1993. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr 122:904–908. doi:10.1016/S0022-3476(09)90015-4.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Aaby P,
    2. Jensen H,
    3. Samb B,
    4. Cisse B,
    5. Sodemann M,
    6. Jakobsen M,
    7. Poulsen A,
    8. Rodrigues A,
    9. Lisse IM,
    10. Simondon F,
    11. Whittle H
    . 2003. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 361:2183–2188. doi:10.1016/S0140-6736(03)13771-3.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Aaby P,
    2. Garly ML,
    3. Nielsen J,
    4. Ravn H,
    5. Martins C,
    6. Balé C,
    7. Rodrigues A,
    8. Benn CS,
    9. Lisse IM
    . 2007. Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: observations from vaccination trials in Guinea-Bissau. Pediatr Infect Dis J 26:247–252. doi:10.1097/01.inf.0000256735.05098.01.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Noe AR,
    2. Espinosa D,
    3. Li X,
    4. Coelho-Dos-Reis JG,
    5. Funakoshi R,
    6. Giardina S,
    7. Jin H,
    8. Retallack DM,
    9. Haverstock R,
    10. Allen JR,
    11. Vedvick TS,
    12. Fox CB,
    13. Reed SG,
    14. Ayala R,
    15. Roberts B,
    16. Winram SB,
    17. Sacci J,
    18. Tsuji M,
    19. Zavala F,
    20. Gutierrez GM
    . 2014. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. PLoS One 9:e107764. doi:10.1371/journal.pone.0107764.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mettens P,
    2. Dubois PM,
    3. Demoitié MA,
    4. Bayat B,
    5. Donner MN,
    6. Bourguignon P,
    7. Stewart VA,
    8. Heppner DG,
    9. Garçon N,
    10. Cohen J
    . 2008. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 26:1072–1082. doi:10.1016/j.vaccine.2007.12.018.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Pichyangkul S,
    2. Kum-Arb U,
    3. Yongvanitchit K,
    4. Limsalakpetch A,
    5. Gettayacamin M,
    6. Lanar DE,
    7. Ware LA,
    8. Stewart VA,
    9. Heppner DG,
    10. Mettens P,
    11. Cohen JD,
    12. Ballou WR,
    13. Fukuda MM
    . 2008. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S-AS01B vaccine in rhesus primates. Infect Immun 76:229–238. doi:10.1128/IAI.00977-07.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Beery AK,
    2. Zucker I
    . 2011. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 35:565–572. doi:10.1016/j.neubiorev.2010.07.002.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
RTS,S Malaria Vaccine and Increased Mortality in Girls
Sabra L. Klein, Frank Shann, William J. Moss, Christine S. Benn, Peter Aaby
mBio Apr 2016, 7 (2) e00514-16; DOI: 10.1128/mBio.00514-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mBio article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
RTS,S Malaria Vaccine and Increased Mortality in Girls
(Your Name) has forwarded a page to you from mBio
(Your Name) thought you would be interested in this article in mBio.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
RTS,S Malaria Vaccine and Increased Mortality in Girls
Sabra L. Klein, Frank Shann, William J. Moss, Christine S. Benn, Peter Aaby
mBio Apr 2016, 7 (2) e00514-16; DOI: 10.1128/mBio.00514-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • GUEST EDITORIAL
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About mBio
  • Editor in Chief
  • Board of Editors
  • AAM Fellows
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Article Types
  • Ethics
  • Contact Us

Follow #mBio

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2150-7511